Academic Journal
Development of a dried blood spot sampling method towards therapeutic monitoring of radotinib in the treatment of chronic myeloid leukaemia
| العنوان: | Development of a dried blood spot sampling method towards therapeutic monitoring of radotinib in the treatment of chronic myeloid leukaemia |
|---|---|
| المؤلفون: | Lee, Jihyun, Jung, Su Young, Choi, Mi-Yeon, Park, Ji-su, Park, Su-kyoung, Lim, Seon-Ah, Cho, Kyung Hee, Oh, Soo Yeon, Ha, Jungeun, Kim, Dong-Wook, Lee, Jangik |
| المساهمون: | Lee, Jangik |
| بيانات النشر: | Blackwell Publishing Inc. |
| سنة النشر: | 2020 |
| المجموعة: | Seoul National University: S-Space |
| الوصف: | What is known and objective Dried blood spot (DBS) sampling is a minimally invasive method of blood sampling that enables monitoring of drug concentrations to be more convenient. This study aimed at developing a DBS sampling method for an accurate and precise prediction of radotinib plasma concentrations (C-p) in patients with chronic myeloid leukaemia (CML). Methods Dried blood spot and venous blood samples were simultaneously collected from fifty CML patients who had been receiving radotinib for at least a week. Radotinib concentrations were measured using a high-performance liquid chromatographic method with tandem mass spectrometric detection. Unmeasured C-p was predicted directly based on a Deming regression between DBS concentrations (C-DBS) and C-p. Unmeasured C-p was also predicted from C-DBS corrected by each patient's haematocrit (Hct). Both prediction methods were evaluated for their accuracy and precision using Deming regression and Bland-Altman analysis. Results and discussion The Deming regression equation between C-DBS and C-p was obtained as follows: C-p = 1.34 center dot C-DBS + 4.26 (r(2) = .97). C-p was directly predictable using C-p,C-pred1 = 1.34 center dot C-DBS + 4.26. With Hct correction, C-p was alternatively predictable using C-p,C-pred2 = C-DBS/ (1-Hct + Hct(2)). The slopes of Deming regression line between predicted and measured C-p were 0.99 and 1.02 for the direct and Hct-corrected method, respectively. The mean biases (accuracy) were -0.44% and 1.6% with the 95% limits of agreement (precision) of -22.4% to 21.5% and -20.5% to 23.7%, respectively. More than 93% of predicted and measured C-p pairs had their differences within 20% of the mean of each pair in both methods. What is new and conclusions Radotinib C-DBS are highly correlated with radotinib C-p. Radotinib C-p can be accurately and precisely predicted from C-DBS using direct or Hct-corrected prediction methods. Both appear to be appropriate for the therapeutic monitoring of radotinib in patients with CML. ; N ; 1 |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| تدمد: | 0269-4727 |
| Relation: | Journal of Clinical Pharmacy and Therapeutics, Vol.45 No.5, pp.1-8; https://hdl.handle.net/10371/179940; 000511000400001; 2-s2.0-85079053702; 104640 |
| الاتاحة: | https://hdl.handle.net/10371/179940 |
| رقم الانضمام: | edsbas.ED1CE5E4 |
| قاعدة البيانات: | BASE |
كن أول من يترك تعليقا!